Biognosys, a Schlieren, Switzerland-based proteomics company, secured USD$5m in an extended series C round.
Backers were not disclosed.
The company intends to use the funds to extend its commercial operations and to accelerate the development of next generation proteomics workflows and products for high-content and high-throughput protein analysis.
Led by Dr. Oliver Rinner, CEO and co-founder, Biognosys offers innovative services and products for highly multiplexed protein quantification. Its technology, which quantifies proteins with precision and depth, relies on mass spectrometry, which allows simultaneous quantification of thousands of proteins in a single experiment.
Biognosys’ contract research services and tools are applied in biomarker research, drug and target discovery, pathway modeling, mechanisms of action studies and many other areas. Its market leading expertise in proteomics is recognized by pharma and biotech companies like Novartis, AstraZeneca, Moderna Therapeutics, and world’s leading academic institutions.